iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 2,500 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $100.11, for a total transaction of $250,275.00. Following the transaction, the chief executive officer owned 2,247,500 shares of the company’s stock, valued at $224,997,225. This trade represents a 0.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

iRadimed Trading Down 1.2%

IRMD opened at $98.94 on Wednesday. The firm has a market cap of $1.26 billion, a P/E ratio of 56.54 and a beta of 1.12. iRadimed Corporation has a 12 month low of $47.48 and a 12 month high of $107.90. The stock has a 50-day moving average of $100.08 and a 200 day moving average of $88.16.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The firm had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, research analysts forecast that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Monday, February 23rd were paid a $0.20 dividend. This is an increase from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend was Monday, February 23rd. iRadimed’s payout ratio is currently 45.71%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Roth Mkm reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. Finally, Lake Street Capital reissued a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research report on Wednesday, February 11th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, iRadimed has a consensus rating of “Moderate Buy” and an average target price of $120.00.

Institutional Investors Weigh In On iRadimed

Several hedge funds have recently made changes to their positions in IRMD. Vanguard Group Inc. grew its position in shares of iRadimed by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock worth $40,313,000 after buying an additional 5,475 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of iRadimed by 6.5% in the second quarter. Geode Capital Management LLC now owns 261,386 shares of the medical equipment provider’s stock valued at $15,630,000 after acquiring an additional 15,996 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in iRadimed by 410.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after acquiring an additional 205,783 shares during the period. Dimensional Fund Advisors LP grew its holdings in iRadimed by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 217,129 shares of the medical equipment provider’s stock worth $21,123,000 after acquiring an additional 2,578 shares in the last quarter. Finally, Ranger Investment Management L.P. grew its holdings in iRadimed by 7.4% during the 2nd quarter. Ranger Investment Management L.P. now owns 214,840 shares of the medical equipment provider’s stock worth $12,845,000 after acquiring an additional 14,730 shares in the last quarter. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.